On this page
Evidence update · 24 September 2026. Novo Nordisk released REIMAGINE 2 topline figures on 2 February. The full phase 3 trial report was subsequently published online on 7 June in The Lancet Diabetes & Endocrinology. This guide now distinguishes the published findings from the earlier company announcement. It is about adults with type 2 diabetes receiving metformin, with or without an SGLT2 inhibitor; it should not be read as a result for every person seeking weight management.
The answer in 30 seconds
At week 68, the trial’s primary outcome—change in HbA1c—favoured the higher-dose cagrilintide–semaglutide combination over semaglutide 2.4 mg alone. The published estimated difference was 0.16 percentage points in HbA1c reduction (95% confidence interval 0.05 to 0.27 percentage points in favour of the combination; p=0.0035). This is a specific glycaemic result in the studied population, not a general claim about long-term cardiovascular outcomes or approval in Australia.
Trial snapshot: published report versus first announcement
| Question | What the evidence says |
|---|---|
| Design | Randomised, double-blind, active- and placebo-controlled phase 3 trial in 30 countries; 68 weeks. |
| Participants | The final paper reports 2,713 randomised adults. The February company announcement described 2,728 participants. For analysed groups and participant flow, use the final publication. |
| Primary comparison | CagriSema 2.4 mg/2.4 mg (603 randomised) versus semaglutide 2.4 mg (605 randomised), both once weekly, for HbA1c change at week 68. |
| Published HbA1c result | Mean change of −1.91 percentage points versus −1.75 percentage points under the efficacy estimand; estimated difference −0.16 (95% CI −0.27 to −0.05; p=0.0035). |
| Weight headline | The sponsor’s February announcement reported estimated weight changes of −14.2% versus −10.2% under its efficacy estimand. Keep this labelled as an announcement figure when quoting it; it is a different outcome from the paper’s primary HbA1c endpoint. |
| Any adverse event | Reported by 86.9% (524/603) in the higher-dose combination group and 81.2% (491/605) with semaglutide 2.4 mg. Gastrointestinal disorders were the most common adverse events in active treatment groups. |
Why the two HbA1c figures for semaglutide differ
The early announcement rounded the semaglutide 2.4 mg estimate to −1.76 percentage points; the published abstract reports −1.75. We use the peer-reviewed figure for the primary comparison. The February release also provided a treatment-regimen estimand, which considers treatment effects regardless of adherence: −1.80 versus −1.68 percentage points for HbA1c, and −12.9% versus −9.2% for weight. Those estimates answer a different question from the efficacy estimand. Do not switch between them in a single comparison without naming the method.
What the published paper adds
The paper describes the trial design, randomisation, analysis population and participant flow. Of 2,713 randomised participants, 2,595 completed the study and 2,376 were still on treatment at week 68. Its primary result has a confidence interval and a prespecified comparison. The trial was funded by Novo Nordisk, which also employed some authors; funding and declared interests should remain visible alongside the findings.
The result supports better glycaemic control on the measured endpoint for the combination in this population. It does not establish that the combination prevents heart attacks, is suitable for an individual reader, or has a particular Australian approval status. Those are separate questions with separate evidence requirements.
Australian context and next checks
A publication, trial registration or overseas regulatory submission is not an Australian Register of Therapeutic Goods (ARTG) entry. Check the TGA’s ARTG search guidance for the current Australian status rather than assuming it from a trial result. This page provides scientific context only and no treatment or dosing advice.
Primary evidence and reading path
- Buse and colleagues, REIMAGINE 2 trial report, published online 7 June 2026; DOI 10.1016/S2213-8587(26)00125-7. PubMed also lists a subsequent correction; readers should consult the linked record and journal version.
- ClinicalTrials.gov record NCT06065540 for the registered design and outcomes.
- Novo Nordisk announcement of 2 February 2026 for the original topline estimates, labelled as sponsor-reported.
For a reusable method, read our trial-registry guide and press-release versus paper guide. Editorial note: This is an educational evidence summary, not medical advice.
How to cite this article
CagriSema REIMAGINE 2: What the Published Phase 3 Trial Shows. Elite Peps Australia. Published 14 September 2026; updated 24 September 2026. https://elitepepsaustralia.com/cagrisema-reimagine-2-results-2026/
Source checks: Consult the primary studies, trial records and regulator documents linked in this article for current evidence and status. Publication and update dates do not by themselves indicate an evidence review.